2025-04-19 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

**0. Key Figures & Initial Analysis:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical devices, and consumer goods company.  The provided data shows mixed performance compared to the S&P 500 (VOO). While JNJ has demonstrated consistent revenue and profitability, its cumulative return lags behind the market benchmark.  Further analysis is needed to assess long-term prospects.


**1. Performance Comparison with S&P 500:**

* **JNJ Cumulative Return:** 39.81%
* **VOO (S&P 500) Cumulative Return:** 76.18%
* **Return Difference:** -36.4%
* **Relative Deviation:** 41.4% (This indicates JNJ's performance is below the S&P 500,  specifically in the 41.4th percentile of its historical range of underperformance relative to the S&P 500.)


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 33.0% | 55.5% | 1.0% | 0.1 | 275.3 |
| 2016-2018  | 15.0% | 10.7% | -6.0% | -0.0 | 261.2 |
| 2017-2019  | 25.0% | 10.7% | -8.0% | 0.7 | 303.6 |
| 2018-2020  | 20.0% | 59.4% | -10.0% | 0.5 | 336.4 |
| 2019-2021  | 36.0% | 59.5% | -25.0% | 0.4 | 374.9 |
| 2020-2022  | 8.0% | 61.3% | -1.0% | 0.3 | 397.3 |
| 2021-2023  | -17.0% | 61.3% | -38.0% | 0.4 | 363.2 |
| 2022-2024  | -31.0% | 61.3% | -51.0% | 0.3 | 345.7 |
| 2023-2025  | 1.0% | 69.7% | -13.0% | 0.1 | 379.5 |

The Alpha values are inconsistent, suggesting variable outperformance relative to the market. The Beta values generally indicate lower than average market sensitivity.  However, the negative CAGRs in recent years are a significant concern.


**2. Recent Price Movements:**

* **Closing Price:** $157.47
* **5-Day Moving Average:** $154.22
* **20-Day Moving Average:** $156.77
* **60-Day Moving Average:** $157.93

The price is slightly below the 60-day moving average, suggesting potential for upside, but the recent price change is positive (+$2.31), indicating a recent uptrend.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.42 (Medium Risk)
* **RSI:** 43.01 (Slightly below neutral; suggesting neither overbought nor oversold conditions)
* **PPO:** 0.036 (Positive, suggesting bullish momentum, though relatively weak)
* **20-Day Relative Strength Change:** +3.7 (Short-term upward trend)
* **Expected Return (vs. S&P 500, long-term):** -37.0%  This indicates a significant expected underperformance against the S&P 500 over the long term (2+ years).  The recent price increase (+2.31) doesn't significantly alter this long-term outlook.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-23 | $1.12  | $22.47 B     |
| 2024-07-25 | $1.95  | $22.45 B     |
| 2024-05-01 | $1.35  | $21.38 B     |
| 2024-02-16 | $1.68  | $21.39 B     |
| 2023-10-27 | $10.32 | $21.35 B     |

EPS shows significant variability, with a very high outlier in Oct 2023. This needs further investigation to understand the cause. Revenue remains relatively stable.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |
| 2023-12-31 | $21.39B  | 68.23%        |

Revenue is relatively consistent, and profit margins are high and stable.


**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-12-31 | $71.49B  | 4.80%   |
| 2024-09-30 | $70.16B  | 3.84%   |
| 2024-06-30 | $71.54B  | 6.55%   |
| 2024-03-31 | $70.02B  | 4.65%   |
| 2023-12-31 | $68.77B  | 5.89%   |

Equity fluctuates slightly, and ROE shows some variability, but generally remains positive.


**6. Overall Analysis:**

JNJ shows strong revenue and profitability, but its stock performance significantly lags the S&P 500. The inconsistent Alpha values, negative recent CAGRs and a projected long-term underperformance relative to the market are concerning.  The high variability in EPS warrants further investigation. While the company's fundamentals appear sound, the recent market performance and projected future underperformance suggest caution.  Further due diligence, including a deeper analysis of the outlier EPS value and an examination of the company's future growth prospects, is crucial before making any investment decisions.  The current data suggests that JNJ may not be a suitable investment for those seeking market-beating returns in the long term.
